Literature DB >> 24710569

FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells.

X Liu1, S N Robinson1, T Setoyama2, S S Tung1, L D'Abundo2, M Y Shah2, H Yang1, E Yvon1, N Shah1, H Yang1, M Konopleva3, G Garcia-Manero3, I McNiece1, K Rezvani1, G A Calin4, E J Shpall1, S Parmar1.   

Abstract

Exact mechanism of action of umbilical cord blood (CB)-derived regulatory T cells (Tregs) in the prevention of GVHD remains unclear. On the basis of selective overexpression of peptidase inhibitor 16 in CB Tregs, we explored the related p53 pathway, which has been shown to negatively regulate miR15a/16 expression. Significantly lower levels of miR15a/16 were observed in CB Tregs when compared with conventional CB T cells (Tcons). In a xenogeneic GVHD mouse model, lower levels of miR15a/16 were also found in Treg recipients, which correlated with a better GVHD score. Forced overexpression of miR15a/16 in CB Tregs led to inhibition of FOXP3 and CTLA4 expression and partial reversal of Treg-mediated suppression in an allogeneic mixed lymphocyte reaction that correlated with the reversal of FOXP3 demethylation in CB Tregs. On the other hand, miR15a/16 knockdown in CB Tcons led to expression of FOXP3 and CTLA4 and suppression of allogeneic lymphocyte proliferation. Using a luciferase-based mutagenesis assay, FOXP3 was determined to be a direct target of miR15a and miR16. We propose that miR15a/16 has an important role in mediating the suppressive function of CB Tregs and these microRNAs may have a 'toggle-switch' function in Treg/Tcon plasticity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24710569      PMCID: PMC4080423          DOI: 10.1038/bmt.2014.57

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  38 in total

1.  Analyzing real-time PCR data by the comparative C(T) method.

Authors:  Thomas D Schmittgen; Kenneth J Livak
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

2.  Interactions of allogeneic human mononuclear cells in the two-way mixed leucocyte culture (MLC): influence of cell numbers, subpopulations and cyclosporin.

Authors:  T Sato; A Deiwick; G Raddatz; K Koyama; H J Schlitt
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

3.  Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity.

Authors:  S Parmar; S N Robinson; K Komanduri; L St John; W Decker; D Xing; H Yang; J McMannis; R Champlin; M de Lima; J Molldrem; A Rieber; M Bonyhadi; R Berenson; E J Shpall
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

4.  Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous.

Authors:  M F Bachmann; G Köhler; B Ecabert; T W Mak; M Kopf
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

5.  Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells.

Authors:  Ye Zheng; Steven Z Josefowicz; Arnold Kas; Tin-Tin Chu; Marc A Gavin; Alexander Y Rudensky
Journal:  Nature       Date:  2007-01-21       Impact factor: 49.962

6.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

7.  TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells.

Authors:  Song Guo Zheng; Ju Hua Wang; William Stohl; Kyoung Soo Kim; J Dixon Gray; David A Horwitz
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

8.  DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells.

Authors:  Udo Baron; Stefan Floess; Georg Wieczorek; Katrin Baumann; Andreas Grützkau; Jun Dong; Andreas Thiel; Tina J Boeld; Petra Hoffmann; Matthias Edinger; Ivana Türbachova; Alf Hamann; Sven Olek; Jochen Huehn
Journal:  Eur J Immunol       Date:  2007-09       Impact factor: 5.532

9.  Prediction of mammalian microRNA targets.

Authors:  Benjamin P Lewis; I-hung Shih; Matthew W Jones-Rhoades; David P Bartel; Christopher B Burge
Journal:  Cell       Date:  2003-12-26       Impact factor: 41.582

10.  The microRNA.org resource: targets and expression.

Authors:  Doron Betel; Manda Wilson; Aaron Gabow; Debora S Marks; Chris Sander
Journal:  Nucleic Acids Res       Date:  2007-12-23       Impact factor: 16.971

View more
  18 in total

Review 1.  Role of miRNAs in immune responses and immunotherapy in cancer.

Authors:  Maria Angelica Cortez; Simone Anfossi; Rishab Ramapriyan; Hari Menon; Semra Cemre Atalar; Maureen Aliru; James Welsh; George A Calin
Journal:  Genes Chromosomes Cancer       Date:  2019-04       Impact factor: 5.006

2.  microRNA-142-mediated repression of phosphodiesterase 3B critically regulates peripheral immune tolerance.

Authors:  Nelomi Anandagoda; Joanna Cd Willis; Arnulf Hertweck; Luke B Roberts; Ian Jackson; M Refik Gökmen; Richard G Jenner; Jane K Howard; Graham M Lord
Journal:  J Clin Invest       Date:  2019-02-11       Impact factor: 14.808

3.  Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients.

Authors:  L C M Arruda; J C C Lorenzi; A P A Sousa; D L Zanette; P V B Palma; R A Panepucci; D S Brum; A A Barreira; D T Covas; B P Simões; W A Silva; M C Oliveira; K C R Malmegrim
Journal:  Bone Marrow Transplant       Date:  2014-12-08       Impact factor: 5.483

Review 4.  New Insights into Regulatory T Cells: Exosome- and Non-Coding RNA-Mediated Regulation of Homeostasis and Resident Treg Cells.

Authors:  Peiyao Li; Changhong Liu; Zhibin Yu; Minghua Wu
Journal:  Front Immunol       Date:  2016-12-06       Impact factor: 7.561

Review 5.  Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease.

Authors:  Keli L Hippen; Michael Loschi; Jemma Nicholls; Kelli P A MacDonald; Bruce R Blazar
Journal:  Front Immunol       Date:  2018-01-31       Impact factor: 7.561

6.  Expression of Serum microRNAs is Altered During Acute Graft-versus-Host Disease.

Authors:  Rachel E Crossland; Jean Norden; Mateja Kralj Juric; Kile Green; Kim F Pearce; Clare Lendrem; Hildegard T Greinix; Anne M Dickinson
Journal:  Front Immunol       Date:  2017-03-24       Impact factor: 7.561

Review 7.  miRNA Regulation of T Cells in Islet Autoimmunity and Type 1 Diabetes.

Authors:  Martin G Scherm; Carolin Daniel
Journal:  Curr Diab Rep       Date:  2020-07-28       Impact factor: 4.810

Review 8.  The Role of MicroRNAs in Regulatory T Cells.

Authors:  Chao Liu; Nannan Li; Guijian Liu
Journal:  J Immunol Res       Date:  2020-04-02       Impact factor: 4.818

Review 9.  Effects of Non-Coding RNA on Regulatory T Cells and Implications for Treatment of Immunological Diseases.

Authors:  Yuanhanyu Luo; Honglin Wang
Journal:  Front Immunol       Date:  2020-11-20       Impact factor: 7.561

10.  Exosomal miRNA Signatures for Late-Onset Acute Graft-Versus-Host Disease in Allogenic Hematopoietic Stem Cell Transplantation.

Authors:  Seiichiro Yoshizawa; Tomohiro Umezu; Yuu Saitoh; Moritaka Gotoh; Daigo Akahane; Chiaki Kobayashi; Junko H Ohyashiki; Kazuma Ohyashiki
Journal:  Int J Mol Sci       Date:  2018-08-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.